Medicus Pharma Ltd. - Common Stock (NQ:MDCX)

1.524 +0.054 (+3.68%)

Streaming Delayed Price Updated: 9:36 AM EST, Mar 4, 2026 Add to My Watchlist

Price and Volume

Volume	113,220
Open	1.530
Bid (Size)	1.490 (6,500)
Ask (Size)	1.530 (100)
Prev. Close	1.470
Today's Range	1.490 - 1.540
52wk Range	0.9174 - 8.940
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Medicus Pharma To Participate in the 38th Annual Roth Conference

March 03, 2026

Company Exec. Chairman & CEO in a fireside chat is expected to highlight the role of Skinject in an autosomal dominant rare disease, AI-enabled drug development strategy and partnering readiness

From Medicus Pharma Ltd

Via GlobeNewswire

New to The Street to Broadcast Executive Leadership Interviews Featuring Medicus Pharma Ltd. (NASDAQ:MDCX), CitroTech (NYSE:CITR), Vivos Therapeutics, Inc. (NASDAQ:VVOS), and Virtuix Holdings ($VTIX) on Bloomberg Television Tonight at 6:30 PM EST

February 28, 2026

Via ACCESS Newswire

Performance

YTD	-4.7%	-4.7%
1 Month	+28.1%	+28.1%
3 Month	-20.4%	-20.4%
6 Month	-26.7%	-26.7%
1 Year	-59.9%	-59.9%

More News

Medicus Pharma on Bloomberg World

February 12, 2026

Via ACCESS Newswire

New to The Street Signs Six-Part Media Series Featuring Medicus Pharma Ltd.

February 10, 2026

Via ACCESS Newswire

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

February 10, 2026

From Medicus Pharma Ltd

Via GlobeNewswire

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

January 22, 2026

From Medicus Pharma Ltd

Via GlobeNewswire

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

January 20, 2026

From Medicus Pharma Ltd

Via GlobeNewswire

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

January 12, 2026

From Medicus Pharma Ltd

Via GlobeNewswire

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

January 05, 2026

From Medicus Pharma Ltd

Via GlobeNewswire

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

December 22, 2025

Via ACCESS Newswire

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

December 15, 2025

From Medicus Pharma Ltd

Via GlobeNewswire

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

December 05, 2025

Via ACCESS Newswire

Let's take a look at the stocks that are in motion in today's session. ↗

December 04, 2025

Via Chartmill

Disrupting a $6 Billion Skin Cancer Market: The Small-Cap Biotech (MDCX) Advancing a Non-Surgical Patch

December 04, 2025

Via AB Newswire

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

December 01, 2025

Via ACCESS Newswire

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

November 24, 2025

From Medicus Pharma Ltd.

Via GlobeNewswire

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

November 17, 2025

Via ACCESS Newswire

Medicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

November 17, 2025

From Medicus Pharma

Via GlobeNewswire

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

November 14, 2025

Via ACCESS Newswire

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

November 13, 2025

Via ACCESS Newswire

Medicus Pharma Ltd. (NASDAQ: MDCX) and the Patch That Could End Repetitive Cancer Surgeries

November 05, 2025

Via AB Newswire

Emerging Biotech Stars Poised for Multi-Billion-Dollar Breakthroughs (MDCX, ACTU, LTRN, TNXP)

October 30, 2025

Via AB Newswire

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

October 29, 2025

Via ACCESS Newswire

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

October 29, 2025

From Medicus Pharma

Via GlobeNewswire

4 Clinical-Stage Biotechs to Watch as the Sector Rebounds (MDCX, AUPH, LEXX, EDSA)

October 23, 2025

Via AB Newswire

Frequently Asked Questions

Is Medicus Pharma Ltd. - Common Stock publicly traded?

Yes, Medicus Pharma Ltd. - Common Stock is publicly traded.

What exchange does Medicus Pharma Ltd. - Common Stock trade on?

Medicus Pharma Ltd. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Medicus Pharma Ltd. - Common Stock?

The ticker symbol for Medicus Pharma Ltd. - Common Stock is MDCX on the Nasdaq Stock Market

What is the current price of Medicus Pharma Ltd. - Common Stock?

The current price of Medicus Pharma Ltd. - Common Stock is 1.524

When was Medicus Pharma Ltd. - Common Stock last traded?

The last trade of Medicus Pharma Ltd. - Common Stock was at 03/04/26 09:36 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.